Abstract
The formation and spread of infections by multi-resistant bacteria is favoured by the absence of hygienic measures to prevent the spread in hospital settings as well as the frequent use of antibiotics. Overall, approximately 20% of Staphylococcus aureus isolates in Europe are reported as methicillin resistant and cause serious nosocomial infections. Therefore, the worldwide rise in antibiotic resistance in clinical practise has led to the search for alternative methods of selectively destroying pathogens without harming the host tissue. One “new” approach to treat microbial infections uses light in combination with a photosensitizer to induce a phototoxic reaction by reactive oxygen species similar as in photodynamic therapy of skin cancer. In particular, different classes of molecules including porphyrins, phthalocyanines, phenothiazine and fullerenes have demonstrated antimicrobial efficacy against a broad spectrum of multi-resistant bacteria upon irradiation with visible light. Another “new” approach is called bacteriophage therapy, which involves using phages or their products as bioactive agents for the prophylaxis and/or treatment of bacterial infectious diseases. Phages were used topically, orally or systemically and have demonstrated efficacy against Gram (-) bacteria, whereas purified phageencoded agents are also effective against Gram (+) bacteria.
Keywords: Antibacterial, phototoxicity, photosensitizer, phages, bacteriophage-conjugated photosensitizer
Anti-Infective Agents in Medicinal Chemistry
Title: Revitalized Strategies Against Multi-Resistant Bacteria: Antimicrobial Photodynamic Therapy and Bacteriophage Therapy
Volume: 6 Issue: 2
Author(s): Tim Maisch
Affiliation:
Keywords: Antibacterial, phototoxicity, photosensitizer, phages, bacteriophage-conjugated photosensitizer
Abstract: The formation and spread of infections by multi-resistant bacteria is favoured by the absence of hygienic measures to prevent the spread in hospital settings as well as the frequent use of antibiotics. Overall, approximately 20% of Staphylococcus aureus isolates in Europe are reported as methicillin resistant and cause serious nosocomial infections. Therefore, the worldwide rise in antibiotic resistance in clinical practise has led to the search for alternative methods of selectively destroying pathogens without harming the host tissue. One “new” approach to treat microbial infections uses light in combination with a photosensitizer to induce a phototoxic reaction by reactive oxygen species similar as in photodynamic therapy of skin cancer. In particular, different classes of molecules including porphyrins, phthalocyanines, phenothiazine and fullerenes have demonstrated antimicrobial efficacy against a broad spectrum of multi-resistant bacteria upon irradiation with visible light. Another “new” approach is called bacteriophage therapy, which involves using phages or their products as bioactive agents for the prophylaxis and/or treatment of bacterial infectious diseases. Phages were used topically, orally or systemically and have demonstrated efficacy against Gram (-) bacteria, whereas purified phageencoded agents are also effective against Gram (+) bacteria.
Export Options
About this article
Cite this article as:
Maisch Tim, Revitalized Strategies Against Multi-Resistant Bacteria: Antimicrobial Photodynamic Therapy and Bacteriophage Therapy, Anti-Infective Agents in Medicinal Chemistry 2007; 6 (2) . https://dx.doi.org/10.2174/187152107780361634
DOI https://dx.doi.org/10.2174/187152107780361634 |
Print ISSN 1871-5214 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6018 |
Related Articles
-
Recent Advances in Psoriasis Therapy: Trends and Future Prospects
Current Drug Targets Hierarchy of Knowledge Translation: From Health Problems to Ad-Hoc Drug Design
Current Medicinal Chemistry Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Anti-TNF Antibodies in Inflammatory Bowel Disease: Do We Finally Know How it Works?
Current Drug Targets Study of HIV Resistance Mutations Against Antiretrovirals using Bioinformatics Tools
Current HIV Research Four Major Factors Regulate Phosphatidylinositol 3-kinase Signaling Pathway in Cancers Induced by Infection of Human Papillomaviruses
Current Medicinal Chemistry Effective Prodrug Liposome and Conversion to Active Metabolite
Current Drug Metabolism Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy
CNS & Neurological Disorders - Drug Targets Mutations in MicroRNA Genes and Their Binding Sites are Infrequently Associated with Human Colorectal Cancer in the Kashmiri Population
MicroRNA Direct Modification of Bioactive Phenothiazines by Exposure to Laser Radiation
Recent Patents on Anti-Infective Drug Discovery Innovative Cancer Treatments that Augment Radiotherapy or Chemotherapy by the Use of Immunotherapy or Gene Therapy
Recent Patents on Anti-Cancer Drug Discovery The Origin of Lentivirus Research: Maedi-Visna Virus
Current HIV Research The Role of Neuronal Insulin/Insulin-Like Growth Factor-1 Signaling for the Pathogenesis of Alzheimer’s Disease: Possible Therapeutic Implications
CNS & Neurological Disorders - Drug Targets The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) in Cancers: Current Progress and Future Perspectives
Current Medicinal Chemistry Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis
Current Pharmaceutical Design The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases
Current Genomics Solubility Enhancement and Delivery Systems of Curcumin a Herbal Medicine: A Review
Current Drug Delivery Management of Adult Active Tuberculosis Disease in Era of HIV Pandemic, Current Practices and Future Perspectives
Infectious Disorders - Drug Targets Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy
Current Pharmaceutical Design